MA28607B1 - Derives d'aminopyridine utiles comme agonistes de dopamine d3 selectifs - Google Patents
Derives d'aminopyridine utiles comme agonistes de dopamine d3 selectifsInfo
- Publication number
- MA28607B1 MA28607B1 MA29488A MA29488A MA28607B1 MA 28607 B1 MA28607 B1 MA 28607B1 MA 29488 A MA29488 A MA 29488A MA 29488 A MA29488 A MA 29488A MA 28607 B1 MA28607 B1 MA 28607B1
- Authority
- MA
- Morocco
- Prior art keywords
- agonists
- derivatives useful
- selective dopamine
- aminopyridine derivatives
- aminopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28607B1 true MA28607B1 (fr) | 2007-05-02 |
Family
ID=34970000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29488A MA28607B1 (fr) | 2004-05-27 | 2006-11-27 | Derives d'aminopyridine utiles comme agonistes de dopamine d3 selectifs |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1758862A1 (fr) |
JP (1) | JP4198183B2 (fr) |
AP (1) | AP2006003824A0 (fr) |
AR (1) | AR049548A1 (fr) |
AU (1) | AU2005247699A1 (fr) |
BR (1) | BRPI0511571A (fr) |
CA (1) | CA2567935C (fr) |
EA (1) | EA200601982A1 (fr) |
EC (1) | ECSP067029A (fr) |
GT (1) | GT200500125A (fr) |
IL (1) | IL179314A0 (fr) |
MA (1) | MA28607B1 (fr) |
MX (1) | MXPA06013786A (fr) |
NL (1) | NL1029139C2 (fr) |
NO (1) | NO20065326L (fr) |
PA (1) | PA8635101A1 (fr) |
PE (1) | PE20060366A1 (fr) |
SV (1) | SV2005002129A (fr) |
TW (1) | TW200609216A (fr) |
UY (1) | UY28925A1 (fr) |
WO (1) | WO2005115985A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
SG172898A1 (en) * | 2009-02-13 | 2011-08-29 | Bayer Schering Pharma Ag | Fused pyrimidines |
CA2795408C (fr) * | 2010-04-12 | 2018-03-13 | Supernus Pharmaceuticals Inc. | Procedes de fabrication de sels de viloxazine et leurs nouveaux polymorphes |
US9504949B2 (en) | 2011-06-30 | 2016-11-29 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and methods |
GB2543296A (en) * | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
TWI806385B (zh) | 2016-07-20 | 2023-06-21 | 瑞士商諾華公司 | 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 |
CA3136151A1 (fr) * | 2019-04-12 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composes agonistes du recepteur d3; procedes de preparation; intermediaires de ceux-ci; et leurs procedes d'utilisation |
MX2022006176A (es) | 2019-11-22 | 2022-08-17 | Incyte Corp | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. |
EP4164641A1 (fr) | 2020-06-16 | 2023-04-19 | Incyte Corporation | Inhibiteurs d'alk2 pour le traitement de l'anémie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
ES2339767T3 (es) * | 2002-12-10 | 2010-05-25 | Pfizer Inc. | Derivados de morfolina para usar como agonistas de dopamina en el tratamiento de la disfuncion sexual entre otros. |
-
2005
- 2005-05-17 EP EP05747191A patent/EP1758862A1/fr not_active Withdrawn
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/fr active Application Filing
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 CA CA002567935A patent/CA2567935C/fr not_active Expired - Fee Related
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SV2005002129A (es) | 2005-12-13 |
GT200500125A (es) | 2006-01-10 |
AP2006003824A0 (en) | 2006-12-31 |
IL179314A0 (en) | 2007-03-08 |
NL1029139A1 (nl) | 2005-11-30 |
NO20065326L (no) | 2006-12-19 |
PA8635101A1 (es) | 2006-05-16 |
MXPA06013786A (es) | 2007-01-25 |
AR049548A1 (es) | 2006-08-16 |
AU2005247699A1 (en) | 2005-12-08 |
TW200609216A (en) | 2006-03-16 |
BRPI0511571A (pt) | 2008-01-02 |
NL1029139C2 (nl) | 2006-06-19 |
PE20060366A1 (es) | 2006-05-15 |
JP4198183B2 (ja) | 2008-12-17 |
ECSP067029A (es) | 2006-12-29 |
CA2567935C (fr) | 2009-10-27 |
CA2567935A1 (fr) | 2005-12-08 |
UY28925A1 (es) | 2005-12-30 |
EA200601982A1 (ru) | 2007-04-27 |
JP2008500331A (ja) | 2008-01-10 |
EP1758862A1 (fr) | 2007-03-07 |
WO2005115985A1 (fr) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28607B1 (fr) | Derives d'aminopyridine utiles comme agonistes de dopamine d3 selectifs | |
DK1735304T3 (da) | Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister | |
IL184901A0 (en) | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors | |
ZA200802453B (en) | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists | |
DK1868999T3 (da) | Pyridin-3-carboxamidderivater som omvendte CB1-agonister | |
PT2094263E (pt) | Derivados da 2-adamantil-butiramida como inibidores seletivos da 11-beta-hsd1 | |
DOP2007000080A (es) | Piridin [3,4-b] pirazinonas | |
HK1124233A1 (en) | Quinoline derivatives as antibacterical agents | |
HK1098156A1 (en) | Phenyl derivatives as ppar agonists | |
ITUD20060182A1 (it) | "metodo di perforazione" | |
IL186150A0 (en) | Novel thiophene derivatives as sphingosine-1-1phosphate-1 receptor agonists | |
ATE481383T1 (de) | 3-aza-bicycloä3.1.0ühexanderivate | |
MA28686B1 (fr) | Derives de pyrrolopyridine | |
ZA200709086B (en) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
ZA200804762B (en) | 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors | |
SI1924561T1 (sl) | 6-arilalkilamino-2,3,4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja | |
HK1099297A1 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
MA28461B1 (fr) | Derives d'heteroaryl- et phenylsulfamoyle substitues | |
ATE384697T1 (de) | 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten | |
IL198462A0 (en) | Diazepane-acetamide derivatives as selective 11??-hsd1 inhibitors | |
PL378342A1 (pl) | Pochodne 2-piperydonu jako agoniści prostaglandyn | |
ATE396724T1 (de) | 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer | |
DK1899324T3 (da) | Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister | |
IL193155A0 (en) | Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents | |
ZA200706672B (en) | 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors |